# EU-1-16-1161_public-assessment-report_20170316_20170316_movymia-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES HEALTH
10 November 2016
EMA/88527/2017
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Movymia
International non-proprietary name: teriparatide
Procedure No. EMEA/H/C/004368/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential nature
deleted.
30 Churchill Place . Canary Wharf . London E14 5EU . United Kingdom
Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520
Send a question via our website www.ema.europa.eu/contact
An agency of the European Union
Table of contents
1. Background information on the procedure
8
1.1. Submission of the dossier
8
1.2. Steps taken for the assessment of the product
10
2. Scientific discussion
11
2.1. Introduction
Error! Bookmark not defined.
2.2. Quality aspects
Error! Bookmark not defined.
2.2.1. Introduction
13
2.2.2. Active Substance
13
2.2.3. Finished Medicinal Product.
16
2.2.4. Discussion on chemical, pharmaceutical and biological aspects
14
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspectsError! Bookmark not
defined.
2.2.6. Recommendation(s) for future quality development ... Error! Bookmark not defined.
2.3. Non-clinical aspects
Error! Bookmark not defined.
2.3.1. Introduction
Error! Bookmark not defined.
2.3.2. Pharmacology
Error! Bookmark not defined.
2.3.3. Pharmacokinetics
Error! Bookmark not defined.
2.3.4. Toxicology
Error! Bookmark not defined.
2.3.5. Ecotoxicity/environmental risk assessment
Error! Bookmark not defined.
2.3.6. Discussion on non-clinical aspects
Error! Bookmark not defined.
2.3.7. Conclusion on non-clinical aspects
Error! Bookmark not defined.
2.4. Clinical aspects
Error! Bookmark not defined.
2.4.1. Pharmacokinetics
Error! Bookmark not defined.
2.4.2. Pharmacodynamics
Error! Bookmark not defined.
2.4.3. Discussion on clinical pharmacology.
Error! Bookmark not defined.
2.4.4. Conclusions on clinical pharmacology
Error! Bookmark not defined.
2.4.5. Clinical efficacy
Error! Bookmark not defined.
2.4.6. Discussion on clinical efficacy.
Error! Bookmark not defined.
2.4.7. Conclusions on clinical efficacy
Error! Bookmark not defined.
2.5. Clinical safety
Error! Bookmark not defined.
2.5.1. Discussion on clinical safety
Error! Bookmark not defined.
2.5.2. Conclusions on clinical safety
Error! Bookmark not defined.
2.6. Risk Management Plan.
Error! Bookmark not defined.
2.7. Pharmacovigilance
Error! Bookmark not defined.
2.8. Product information
Error! Bookmark not defined.
2.8.1. User consultation
Error! Bookmark not defined.
2.8.2. Quick Response (QR) code
Error! Bookmark not defined.
3. Benefit-Risk Balance
Error! Bookmark not defined.
3.1.1. Importance of favourable and unfavourable effects .... Error! Bookmark not defined.
Assessment report
EMA/88527/2017
Page 2/47
